Drug has acquisition cost is an important component in the analysis of economic and clinical outcomes in the treatment of respiratory tract growth infections (RTIs). However, bacterial resistance has emerged as a crucial variable that must also be considered. Drug-resistant infections result in appropriate more expensive drug therapy, longer hospital stays, and increased mortality. The high prevalence of community-acquired pneumonia (CAP), as well as infections the continuing growth in resistant pathogens, make RTIs an appropriate model for studying methods of cost-containment without sacrificing clinical outcome.(CAP), The University of Kentucky Medical Center has developed a uniform CAP treatment pathway to minimize costs and maximize outcomes. First-line monotherapy, therapy in this model is doxycycline monotherapy, high-dose amoxicillin plus azithromycin, or levofloxacin monotherapy. One major future concern in selecting without antibacterial agents for CAP is the spread of macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae.

To and determine the clinical importance of Campylobacter pyloridis infection, its association with gastric inflammation, and the response to drug therapy, patients on with a duodenal or gastric ulcer (n = 63), patients with nonulcer dyspepsia (n = 240), and asymptomatic volunteers (n association = 34) were studied. In a prospective longitudinal study, the type, intensity, and distribution of inflammation in antral biopsy specimens specimens were correlated with the presence of C. pyloridis. Campylobacter pyloridis was cultured from antral biopsy specimens in 98% of the of ulcer patients, 70% of the nonulcer dyspepsia patients, and 20% of the asymptomatic volunteers. The dependency of chronic active gastritis after on the presence of C. pyloridis was shown by an association of gastritis with positive culture and healing of gastritis culture with negative culture after various therapeutic regimens. Spontaneous disappearance of C. pyloridis never occurred. Colloidal bismuth subcitrate, amoxicillin, and the colonization combination of colloidal bismuth subcitrate and amoxicillin were effective therapies in eradicating C. pyloridis. Recolonization with the same bacterial subtype or and recurrence of gastritis frequently occurred within 1 mo after initial eradication. In this study we demonstrate ultimate normalization of (n gastric mucosa after successful eradication of C. pyloridis. Especially complete normalization of gastric mucosa after amoxicillin monotherapy provides additional strong its evidence for a true cause-effect relationship between C. pyloridis colonization and gastritis.

The success effects of broad-spectrum antibiotic and placebo therapy in patients with chronic obstructive pulmonary disease in exacerbation were compared in a in randomized, double-blinded, crossover trial. Exacerbations were defined in terms of increased dyspnea, sputum production, and sputum purulence. Exacerbations were followed intervention at 3-day intervals by home visits, and those that resolved in 21 days were designated treatment successes. Treatment failures included home exacerbations in which symptoms did not resolve but no intervention was necessary, and those in which the patient's condition deteriorated but so that intervention was necessary. Over 3.5 years in 173 patients, 362 exacerbations were treated, 180 with placebo and 182 antibiotic. with antibiotic. The success rate with placebo was 55% and with antibiotic 68%. The rate of failure with deterioration was 362 19% with placebo and 10% with antibiotic. There was a significant benefit associated with antibiotic. Peak flow recovered more rapidly and with antibiotic treatment than with placebo. Side effects were uncommon and did not differ between antibiotic and placebo.

BACKGROUND:months, It is uncertain whether treatment of Helicobacter pylori infection relieves symptoms in patients with nonulcer, or functional, dyspepsia. METHODS: We were conducted a double-blind, multicenter trial of patients with H. pylori infection and dyspeptic symptoms (moderate-to-very-severe pain and discomfort centered in group), the upper abdomen). Patients were excluded if they had a history of peptic ulcer disease or gastroesophageal reflux disease and mg had abnormal findings on upper endoscopy. Patients were randomly assigned to seven days of treatment with 20 mg of omeprazole the twice daily, 1000 mg of amoxicillin twice daily, and 500 mg of clarithromycin twice daily or with omeprazole alone and and then followed up for one year. Treatment success was defined as the absence of dyspeptic symptoms or the presence of of minimal symptoms on any of the 7 days preceding the 12-month visit. RESULTS: Twenty of the 348 patients were excluded likely after randomization because they were not infected with H. pylori, were not treated, or had no data available. For the and remaining 328 patients (164 in each group), treatment was successful for 27.4 percent of those assigned to receive omeprazole and disease antibiotics and 20.7 percent of those assigned to receive omeprazole alone (P= .17; absolute difference between groups, 6.7 percent; 95 percent patients confidence interval,-2.6 to 16. ). After 12 months, gastritis had healed in 75. percent of the patients in the group peptic given omeprazole and antibiotics and in 3. percent of the patients in the omeprazole group (P< .001); the respective rates of and H. pylori eradication were 79 percent and 2 percent. In the group given omeprazole and antibiotics, the rate of treatment on success among patients with persistent H. pylori infection was similar to that among patients in whom the infection was eradicated months, (26 percent vs. 31 percent). There were no significant differences between the groups in the quality of life after treatment.BACKGROUND: CONCLUSIONS: In patients with nonulcer dyspepsia, the eradication of H. pylori infection is not likely to relieve symptoms.

BACKGROUND:(21 The eradication of Helicobacter pylori infection is beneficial in patients with gastric or duodenal ulcers. The value of eradicating the the infection in patients with dyspepsia and no evidence of ulcer disease is not known. METHODS: We performed a randomized, placebo-controlled percent) trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of (158 amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin),(maximal and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms of of dyspepsia in patients with H. pylori infection but no evidence of ulcer disease on upper gastrointestinal endoscopy. Symptoms were with assessed with the Glasgow Dyspepsia Severity Score, with resolution of symptoms defined as a score of or 1 in than the preceding six months (maximal score, 20). One year later the patients were assessed to determine the frequency of the randomized, resolution of symptoms. RESULTS: One month after the completion of treatment, 132 of 150 patients (88 percent) in the group times assigned to received omeprazole and antibiotics had a negative test for H. pylori, as compared with 7 of 152 (5 duodenal percent) in the group assigned to receive omeprazole alone. One year later, dyspepsia had resolved in 33 of 154 patients twice (21 percent) in the group given omeprazole and antibiotics, as compared with 11 of 154 (7 percent) in the group for given omeprazole alone (95 percent confidence interval for the difference, 7 to 22 percent; P< .001). Among the patients in the of group given omeprazole and antibiotics, the symptoms resolved in 26 of the 98 patients (27 percent) who had had symptoms (21 for five years or less, as compared with 7 of the 56 patients (12 percent) who had had symptoms for BACKGROUND: more than five years (P= .03). CONCLUSIONS: In patients with H. pylori infection and nonulcer, or functional, dyspepsia, treatment with omeprazole compared and antibiotics to eradicate the infection is more likely to resolve symptoms than treatment with omeprazole alone.

Campylobacter amoxycillin pyloridis colonization of the stomach may be an etiological factor in gastritis and peptic ulceration. Campylobacter pyloridis produces large amounts whom of urease, and the presence of this enzyme in gastric mucosa usually indicates infection with the organism. In this paper min, we describe the use of a rapid urease test (CLOtest) to detect C. pyloridis infection in gastric mucosal biopsies. In in 141 consecutive endoscopy cases, antral biopsies were taken for culture and histology, and an extra biopsy was inserted into the were CLOtest gel. There were 79 patients infected with C. pyloridis, 78 of whom were detected by CLOtest: 75% were positive CLOtest at 20 min, 92% at 3 h, and 98% at 24 h. There were no false positive results. Eighteen infected were patients were rebiopsied after a course of amoxycillin and bismuth subcitrate. Active chronic gastritis resolved in eight of nine who of were cleared of the organism, but histological gastritis was unchanged in nine patients who were still infected. CLOtest is a and simple, sensitive, and highly specific test that enables the endoscopist to diagnose C. pyloridis infection in the endoscopy room. A organism. negative test after antibiotic therapy correlates with clearance of the bacteria and healing of active gastritis.

BACKGROUND:66.4% Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic and efficacy of omeprazole may be increased. OBJECTIVE: To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori peptic infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin. DESIGN: Prospective cohort study. SETTING: University hospital omeprazole and health service center in Hamamatsu, Japan. PATIENTS: 62 patients with peptic ulcer and H. pylori infection. INTERVENTION: Omeprazole and infection. amoxicillin. MEASUREMENTS: CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer. RESULTS: Cure rates for H.cure pylori infection were 28.6%(95% CI, 13.1% to 48.7%), 60%(CI, 38.6% to 83. %), and 100%(CI, 66.4% to 100%)(95% in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups omeprazole were roughly parallel with cure rates for H. pylori infection. CONCLUSION: The results of the genotyping test for CYP2C19 seem efficacy to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.status

BACKGROUND epithelial & AIMS: Whether Helicobacter pylori eradication resolves intestinal metaplasia and atrophy and whether infection with cagA+ H. pylori is related degree to a specific clinical outcome are not known. The aim of this study was to investigate the role of H.by pylori eradication on the course of intestinal metaplasia (IM) and atrophy in relation to cagA. METHODS: In a large prospective study, study, the cagA status of H. pylori isolated from consecutive dyspeptic patients was related to clinical outcome before and 1 weeks year after successful eradication of H. pylori. At pretreatment and 4-6 weeks and on average 1 year after eradication therapy,superficial the degree of gastritis and the status of H. pylori were assessed by culture and histopathology. RESULTS: Specimens of cagA+from H. pylori were recovered from 122 of 155 (79%) patients infected with H. pylori. Pretreatment degrees of gastritis activity, superficial follow-up epithelial damage, IM, and atrophy were significantly greater in patients infected with cagA+ H. pylori (P < .001). After successful outcome eradication of H. pylori, a significant improvement of activity of gastritis and superficial epithelial damage occurred (P < .001), but H. the degree of IM and atrophy did not change, irrespective of the cagA status. CONCLUSIONS: The usefulness of H. pylori metaplasia eradication to revert precancerous lesions such as IM and atrophy after 1-year follow-up is questionable.

In antibacterial randomized, double-blind trials of antibiotic therapy for acute otitis media that determined both clinical and bacteriologic outcomes, clinical success rates media. were (93%) 236 of 253 for patients with bacteriologic success,(62%) 25 of 40 for those with bacteriologic failure, and clinical (80%) 124 of 155 for those with nonbacterial acute otitis media. These rates were used to calculate the effectiveness of for three strategies for assessing drug efficacy:(1) tympanocentesis and culture before and during therapy (bacteriologic efficacy),(2) tympanocentesis before therapy and and assessment of clinical efficacy in bacterial acute otitis media, and (3) no tympanocentesis and assessment of clinical efficacy in appear clinical (total) acute otitis media. For a drug with a bacteriologic efficacy of 100%, calculated clinical efficacy was 93% for acute bacterial acute otitis media and 89% for clinical acute otitis media. For a drug with bacteriologic efficacy of 27%, a acute rate consistent with no antibacterial therapy, efficacy was 71% for bacterial acute otitis media and 74% for clinical acute otitis 253 media. We conclude that if efficacy is measured by symptomatic response, drugs with excellent antibacterial activity will appear less efficacious (80%) than they really are and drugs with poor antibacterial activity will appear more efficacious than they really are. The predominant otitis phenomenon is that drugs with poor antibacterial activity will appear to be clinically effective in the treatment of acute otitis with media.

From (95% 1986 to 1991, 602 patients with melioidosis were seen in Sappasitprasong Hospital, Ubon Ratchatani, Thailand. The in-hospital mortality was 42%.4.7 Of 118 adult patients followed long-term, 27 (23%) had culture-proven relapses of melioidosis (3 relapsed twice), a relapse rate of patients 15%(95% confidence interval [CI], 11-22) per year. The median time from discharge to relapse was 21 weeks (range, 1-290).The In 44% of patients, relapses included septicemia, and 27% died. Patients with severe disease (multiple foci of infection or septicemia)disease relapsed 4.7 times (95% CI, 1.6-14.1) more frequently than patients with localized melioidosis. Underlying disease was not a risk factor,combination but initial parenteral treatment with ceftazidime reduced the risk of relapse 2-fold (95% CI, 1.1-3.4). Relapses were 3.3 (95% CI,factor, 1.4-9. ) times more frequent following short-course (< or = 8 weeks) oral coamoxiclav than after the oral combination regimen of to chloramphenicol, doxycycline, and cotrimoxazole. Longer oral treatment with either reduced relapse 1.6-fold (95% CI, 1.2-1.9). The optimum choice and duration 42%. of antibiotic treatment to prevent relapse in melioidosis remain to be determined.

OBJECTIVE:during To determine the effect of antibiotic treatment for acute otitis media in children between 6 months and 2 years of 1% age. DESIGN: Practice based, double blind, randomised, placebo controlled trial. SETTING: 53 general practices in the Netherlands. SUBJECTS: 240 children in aged 6 months to 2 years with the diagnosis of acute otitis media. INTERVENTION: Amoxicillin 40 mg/kg/day in three doses.day MAIN OUTCOME MEASURES: Persistent symptoms at day four and duration of fever and pain or crying, or both. Otoscopy at common days four and 11, tympanometry at six weeks, and use of analgesic. RESULTS: Persistent symptoms at day four were less to common in the amoxicillin group (risk difference 13%; 95% confidence interval 1% to 25%). The median duration of fever was was two days in the amoxicillin group versus three in the placebo group (P= .004). No significant difference was observed in duration can of pain or crying, but analgesic consumption was higher in the placebo group during the first 10 days (4.1 v randomised, 2.3 doses, P= .004). In addition, no otoscopic differences were observed at days four and 11, and tympanometric findings at six to weeks were similar in both groups. CONCLUSIONS: Seven to eight children aged 6 to 24 months with acute otitis media acute needed to be treated with antibiotics to improve symptomatic outcome at day four in one child. This modest effect does 240 not justify prescription of antibiotics at the first visit, provided close surveillance can be guaranteed.